The Medicines Company Stock Company Profile

Description

The Medicines Company provides medicines for patients in acute and intensive care hospitals worldwide. The company markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, and for patients undergoing percutaneous coronary intervention; Cleviprex, an intravenous small molecule calcium channel blocker for blood pressure reduction; and Ionsys for the short-term management of acute postoperative pain. It also markets Kengreal, an intravenous small molecule antiplatelet agent for reducing the risk of periprocedural thrombotic events; Minocin IV, an antibiotic for the treatment of bacterial infections; Orbactiv for the treatment of acute bacterial skin and skin structure infections; and ready-to-use formulation of Argatroban for the treatment of thrombosis, as well as acute care generic products for acute cardiovascular, surgery and perioperative care, and serious infectious diseases. The company’s products under development also comprise ABP-700, an intravenous anesthetic agent for moderate or deep sedation and general anesthesia in patients undergoing diagnostic or therapeutic procedures; ALN-PCSsc for the treatment of hypercholesterolemia; Carbavance, an antibiotic agent for the treatment of hospitalized patients with gram-negative bacterial infections; and MDCO-216, a novel biologic product to reverse atherosclerotic plaque development and reduce the risk of ischemic events in patients with ACS. It has a collaboration agreement with Alnylam Pharmaceuticals, Inc,; SciClone Pharmaceuticals; and SymBio Pharmaceuticals Ltd. The Medicines Company was founded in 1996 and is based in Parsippany, New Jersey.